Newly released results from two previously published studies demonstrated patients receiving the maintenance combination asthma therapy SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol achieved bronchodilation, or opening of the airways, within 15 minutes and reported feeling their medication begin to work right away.
A 52-week study examined the long-term safety of the maintenance combination asthma therapy, SYMBICORT Inhalation Aerosol, at up to double the approved dosage. More than 700 patients ages 12 years and older with moderate to severe persistent asthma, and who had been previously treated with inhaled corticosteroids, participated in the study. Safety was evaluated through several assessments, including the incidence of asthma exacerbations and adverse events. The study showed that SYMBICORT, a combination of budesonide, an inhaled corticosteroid, and formoterol, a rapid and long-acting beta2-agonist, had a safety profile similar to one of its mono-components, budesonide.
AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the long-term maintenance treatment of asthma in pediatric patients ages 6 to 11 years old. SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
Results from a pivotal Phase III clinical trial presented today demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in patients who underwent total knee replacement (TKR) surgery. The head-to-head study compared rivaroxaban with the U.S.-approved dosing regimen for enoxaparin, the current standard of care. Data from the RECORD4 clinical trial were presented at the annual meeting of the European Federation of National Associations of Orthopaedics & Traumatology (EFORT). Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.
A new 12-week study examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol, in treating mild to moderate persistent asthma in children ages 6 to 15 years old who were previously treated with an inhaled corticosteroid (ICS).
Winners addressing critical issues including Parkinson's disease and global climate change.
A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM).1 Patients participating in the study were ages 18 years and older with moderate to severe asthma and had been previously treated with inhaled corticosteroids.1 Results were presented today at the International Conference of the American Thoracic Society held in Toronto, May 16-21, 2008.
Asthma is a serious chronic medical condition. About 1.8 million ER visits per year and more than $16 billion in direct and indirect healthcare costs are attributable to the disease. For some, asthma can simply make breathing difficult, for others, it can be potentially life-threatening. Change of season can bring more than asthma triggers; learning to control disease is more than just managing symptoms.
Retrospective chart review in 10 geographic regions throughout the United States presented at Pediatric Academic Societies (PAS) annual meeting. The review evaluated the use of Synagis (palvizumab) as a preventative measure against RSV disease in high-risk infants.
In clinical trial, motavizumab reduced hospitalizations due to respiratory syncytial virus by 83 percent compared to placebo
Today, Cambridge-based biotech Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced the initiation of a multi-center, Phase 2a clinical trial of Azedra (Ultratrace iobenguane I-131 or Ultratrace MIBG) in high-risk pediatric neuroblastoma patients---a type of neuroendocrine cancer that primarily affects children. Occurring in about one in every 7,000 births, neuroblastoma is the most common solid tumor in children outside of the brain.
One4One, a unique program focused on empowering women to help make a difference in the fight against cervical cancer, starts today during National Minority Cancer Awareness Week. One4One urges women to talk to their healthcare provider about ways they can help protect themselves from cervical cancer, while also raising money to increase cervical cancer information programs and other educational services, especially for those who may be at greater risk of developing the disease due to lack of access to information or healthcare.
A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.
High doses of daily caffeine during pregnancy "“ whether from coffee, tea, caffeinated soda or hot chocolate -- cause an increased risk of miscarriage, according a new study by the Kaiser Permanente Division of Research. The study controlled, for the first time, pregnancy-related symptoms of nausea, vomiting and caffeine aversion that tended to interfere with the determination of caffeine's true effect on miscarriage risk.
Researcher who discovered telomerase's role in aging and cell mutation among five women scientists awarded in Paris.
Mothers who reported sleeping five hours or less per day when their babies were six months old had a threefold higher risk for substantial weight retention (11 pounds or more) at their baby's first birthday than moms who slept seven hours per day, according to a new study by Kaiser Permanente and Harvard Medical School / Harvard Pilgrim Health Care.
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of Phase 2 clinical results demonstrating that LymphoStat-B® (belimumab) achieved a sustained improvement in disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was well tolerated through 2.5 years on treatment in combination with standard of care in patients with active systemic lupus erythematosus (SLE).
MedImmune, Inc. today announced it will present three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the company's growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of hospitalization among infants.
According to a new survey released this week in conjunction with the National MS Society's National Conference, many people living with multiple sclerosis (MS) who experience visual, dexterity, and cognitive challenges report that technology plays a vital role in helping them live with the disease. However, relatively few are using the assistive technologies that could help them overcome many of these challenges.
The vast majority of patients who had a successful result with the percutaneous MitraClip device did not need mitral valve surgery three years after their procedure, and many benefited from significantly improved function of the left ventricle (commonly known as reverse remodeling), according to data presented this week at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics symposium.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right